CN109507436A - Application of the ATXN2L as the marker of prediction gastric cancer oxaliplatin primary drug resistance - Google Patents
Application of the ATXN2L as the marker of prediction gastric cancer oxaliplatin primary drug resistance Download PDFInfo
- Publication number
- CN109507436A CN109507436A CN201910022553.XA CN201910022553A CN109507436A CN 109507436 A CN109507436 A CN 109507436A CN 201910022553 A CN201910022553 A CN 201910022553A CN 109507436 A CN109507436 A CN 109507436A
- Authority
- CN
- China
- Prior art keywords
- atxn2l
- oxaliplatin
- gastric cancer
- drug resistance
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the functions and application field of gene and albumen, are related to the new application of plain -2 sample albumen (ATXN2L) of incoordination, disclose application of the ATXN2L as the marker of prediction gastric cancer oxaliplatin primary drug resistance.Present invention provides plain -2 sample albumen (ATXN2L) of incoordination to prepare the purposes in the kit for predicting gastric cancer oxaliplatin primary drug resistance.The present invention confirms the Patients with Gastric Cancer prognosis mala of high ATXN2L expression by clinical samples.First demonstration that the high expression of ATXN2L can be by promoting the formation of intracellular stress granules lead to the primary drug resistance of oxaliplatin.After silencing ATXN2L, stomach cancer cell enhances oxaliplatin sensitivity, grade malignancy reduces.Therefore, ATXN2L can be used as the marker of prediction gastric cancer oxaliplatin primary drug resistance, so as to provide the kit of a noninvasive early diagnosis and dynamic monitoring using the preparation process of available reagent box for prediction gastric cancer oxaliplatin primary drug resistance.
Description
Technical field
The invention belongs to the functions and application field of gene and albumen, are related to plain -2 sample albumen (ATXN2L) of incoordination
New application, more particularly to ATXN2L as prediction gastric cancer oxaliplatin primary drug resistance marker new opplication.
Background technique
Gastric cancer is the common malignant tumour in China, and chemotherapy is treatment means important in Comprehensive Therapy on Gastric Carcinoma.Tumour cell
It is drug resistant to chemotherapeutics to limit chemotherapeutic efficacy, it can frequently result in patient's treatment failure.Chemotherapy resistance includes that primary is resistance to
Medicine and secondary resistance, primary drug resistance refer to tumour itself resistance to drug before receiving drug therapy；Secondary resistance
Refer to tumour script not drug resistance, the emerging drug resistance during chemotherapy.It solves the problems, such as gastric cancer initial drug-resistant and secondary drug resistance is existing
For a big difficulty in tumor research field.
Clinically being usually used in the drug of gastric cancer now includes following a few major class: fluorouracil (fluorouracil, Ka Peita
Shore and S-1), platinum class (cis-platinum and oxaliplatin), taxanes (taxol, docetaxel), the soft ratio of table in anthracyclines
Star and topoisomerase enzyme inhibitor Irinotecan.Wherein, oxaliplatin is third generation platinum-like compounds, its effect and other
Platinum medicine action principle is similar, using intracellular DNA as site of action, in two adjacent guanine residues or guanine and gland
Adduct in chain is formed between purine, to inhibit DNA replication dna and transcription, plays antineoplastic action.Existing research confirms difficult to understand
Husky benefit platinum can significantly improve the prognosis of advanced gastric carcinoma patient, have critical role in chemotherapy of gastric cancer.However, Oxaliplatin-resistant
The case where it occur frequently that, influence chemotherapeutic efficacy.The molecular marker for finding energy aided assessment Oxaliplatin-resistant has important face
Bed meaning.
Incoordination -2 sample albumen of element (Ataxin-2 like, ATXN2L) are that hereditary spinal cerebellum type mutual aid is caused to be lost
Plain (Ataxin-2, the ATXN2) homologous protein of the incoordination of tune.It is considerably less about the research report of ATXN2L at present, it is only known
ATXN2L is only expressed in the cell height of the immortalizations such as embryonic tissue, adult testis and candidate stem cell；ATXN2L can be tied with EpoR
It closes；ATXN2L is overexpressed the generation for promoting stress granules.Whether ATXN2L has an effect in tumour generation, influences tumour progression
Specific mechanism it is not yet clear, need further to be studied.
Summary of the invention
The purpose of the present invention is to provide the new applications of plain -2 sample albumen (ATXN2L) of incoordination.
The first aspect of the invention provides plain -2 sample albumen (ATXN2L) of incoordination as prediction gastric cancer Ao Shali
The application of the marker of platinum primary drug resistance.
The first aspect of the invention provides plain -2 sample albumen (ATXN2L) of incoordination in preparation for predicting gastric cancer
Purposes in the kit of oxaliplatin primary drug resistance.
The further feature of purposes according to the present invention, the kit are the contents according to ATXN2L in sample
Or the variation tendency of content predicts the risk of gastric cancer oxaliplatin primary drug resistance.
The further feature of purposes according to the present invention, the kit are immunohistochemistry or Immunofluorescence test
Kit.
The present invention confirms the Patients with Gastric Cancer prognosis mala of high ATXN2L expression by clinical samples.First demonstration that
The high expression of ATXN2L can be by promoting the formation of intracellular stress granules to lead to the primary drug resistance of oxaliplatin.It is heavy
After silent ATXN2L, stomach cancer cell enhances oxaliplatin sensitivity, grade malignancy reduces.Therefore, ATXN2L can be used as prediction
The marker of gastric cancer oxaliplatin primary drug resistance, so as to be that prediction gastric cancer is difficult to understand husky using the preparation process of available reagent box
Sharp platinum primary drug resistance provides the kit of a noninvasive early diagnosis and dynamic monitoring.
Detailed description of the invention
Fig. 1 is expression of the ATXN2L in human gastric cancer sample and the influence to clinical prognosis.Wherein, (a) figure is shown
Differential expression of the ATXN2L of TCGA database analysis stomach organization and the gastric epithelial tissue of pairing in mRNA level in-site；(b)
Figure shows differential expression of the ATXN2L in protein level of the gastric epithelial tissue of fresh stomach organization sample and pairing；(c)
Figure show immunohistochemistry representative figure (d) gastric cancer of follow-up patient by stages, recurrence, existence it is related to the expression of ATXN2L；(e)
Figure shows influence of the expression of ATXN2L to IV phase patients with gastric cancer Overall survival；(f) figure shows the expression of ATXN2L to the I-III phase
The influence of patients with gastric cancer recurrence-free survival phase；(g) figure shows the interim different influences to the recurrence-free survival phase by stages of I-III；(h)
Figure shows influence of the expression of ATXN2L to the I-II phase patients with gastric cancer recurrence-free survival phase；(i) figure shows the expression pair of ATXN2L
The influence of III phase patients with gastric cancer recurrence-free survival phase.
Fig. 2 is the experimental result picture that ATXN2L resists Apoptosis caused by oxaliplatin.Wherein, (a) figure shows gastric cancer
Cell is stimulated form to change to spindle shape by low concentration oxaliplatin, and this morphologic change is suppressed after silencing ATXN2L；(b)
Figure shows that silencing ATXN2L can reverse EMT caused by low concentration oxaliplatin；(c) figure shows Flow cytometry silencing
Apoptosis in gastric cancer ratio increases compared with control group after oxaliplatin is handled after ATXN2L, the then apoptosis handled through 5 FU 5 fluorouracil
Ratio variation is little；(d) figure shows MTT experiment detection stomach cancer cell cell survival rate after the processing of various concentration oxaliplatin,
Cell survival rate is decreased obviously after silencing ATXN2L；(e) figure shows colony formation, and Ao Shali is added after silencing ATXN2L
Platinum Colony forming number is substantially less than control group；(f) figure shows Flow cytometry active oxygen, is added after silencing ATXN2L
Oxaliplatin active oxygen generates more compared with control group.
Fig. 3 is the experimental result picture for the formation that oxaliplatin causes stress granules by ATXN2L.Wherein, (a) figure is shown
Oxaliplatin stimulation can cause intracellular ATXN2L and G3BP1 expression to increase and intracellular stress granules is caused to be formed；(b)
Figure shows that gradient low concentration oxaliplatin handles stomach cancer cell, and the ATXN2L mRNA gradient of stomach cancer cell increases；(c) figure is shown
Low concentration oxaliplatin handles stomach cancer cell different time, and the ATXN2L mRNA gradient of stomach cancer cell increases；(d) figure shows heavy
Silent ATXN2L expression reduces the formation of the stress granules of oxaliplatin stimulation.
Specific embodiment
One, experimental material
1. tissue specimen
Histotomy: the stomach that Hospital of Southern Medical University row in Guangzhou includes radical correction and palliative resection is chosen
Cancer operation Operated Specimens.
Pathological section is included in standard are as follows: 1. through definitive pathological diagnosis be gastric cancer；2. pathological section comes from stomach primary tumor.
Pathological section exclusion criteria are as follows: 1. pathological diagnosis have dispute；2. clinical treatment is not complete.
According to situation, imageological examination in patient's art, TNM stage is carried out to patient.According to the above standard, it is included in 48 altogether
IV phase and 119 I-III phase stomach organization samples are analyzed, and sample is fixed with 10% formalin, and paraffin embedding, are cut
Piece.
Fresh gastric cancer sample: Hospital of Southern Medical University general surgery Surgery for Gastric Carcinoma sample is chosen.Every takes stomach
Cancerous tissue and each two pieces of cancer beside organism, sample collect put into rapidly in cryopreservation tube it is quick-frozen in liquid nitrogen after be transferred to -80 DEG C of Low-temperature Ices
Cryo-conservation in case.
2. stomach cancer cell line and immortalization gastric epithelial cells strain
Human stomach cancer cell line MKN-45, MGC-803 are all from Hospital of Southern Medical University oncology laboratory, are purchased from
Foleibao Bioisystech Co., Ltd.
3. main agents and consumptive material
Fetal calf serum, 1640 culture mediums are the production of Hyclone company.2000 × PBS powder is purchased from Biosharp company.
It EDTA, is the production of solarbio company without EDTA pancreatin, Tris-Hcl (PH8.8 and PH6.8) is from Shanghai White match biotechnology
Co., Ltd.The reagent that TEMED, 30% polyacrylamide, ammonium persulfate, 10%SDS etc. prepare gel is public purchased from Biosharp
Department.Tris alkali is purchased from Biosharp company.Glycine, SDS powder are the production of Sigma company.Methanol, isopropanol, anhydrous second
Alcohol, chloroform, tween are the production of Guangdong Province's chemical reagent engineering and technological research development centre.Skimmed milk power buying is certainly
Biosharp company.Lowlenthal serum is purchased from Guangzhou Zhuo Sheng Biotechnology Co., Ltd.2000 × TBS powder, primary antibody dilution
Purchased from Biosharp company.Holoprotein extracts kit is the production of Co., Ltd, Nanjing Keygen Biotech.5 × albumen loading buffer
Liquid is purchased from Hangzhou Fu De Biotechnology Co., Ltd.PCR kit for fluorescence quantitative, RNAiso plus, Reverse Transcriptase kit are purchased from
Takara company.DEPC water is the production of Shanghai Sheng Gong bio-engineering corporation.DMSO is the production of Mike woods company.Pvdf membrane is
The production of Millipore company.GAPDH monoclonal antibody, ATXN2L polyclonal antibody are the production of Proteintech company.Sheep
Anti-rabbit secondary antibody is the production of Li-COR company.Dimethylbenzene, sodium citrate buffer, hydrogenperoxide steam generator, DAB working solution, haematoxylin,
Hydrochloric acid, neutral gum are purchased from Guangdong Province's chemical reagent engineering and technological research development centre.SiRNA is the synthesis of Rui Bo company.Slow disease
Malicious shRNA is the building of Ji Kai company.ATXN2L, GAPDH upstream and downstream primer are the synthesis of Shanghai Sheng Gong bio-engineering corporation.It is various
Model Tissue Culture Dish, 6 orifice plates, 12 orifice plates, 96 orifice plates are Corning Incorporated's production.BCA determination of protein concentration kit is Jiangsu
Green skies biotech firm production.Apoptosis detection kit is three arrow biological productions.ROS detection kit is that the green skies in Jiangsu are raw
The production of object company.EDU kit is sharp rich production.The anti-mountant Mounting Medium that is quenched is solarbio company.
Western blot glass plate is the production of U.S. Bio-rad company.
Two, experimental method
1.MTT experiment
(1) it plants plate: by the cell dissociation tested, centrifugation, obtaining precipitating, be added suitable 10% into precipitating
Quan Pei carries out cell count, according to needing 6 × 10 in each experimental port3Cell and experiment hole count cell total required for calculating
Suspension always needs liquid volume according still further to needing 100 μ l to train calculating entirely in each experimental port, calculated cell suspension is added
Into 15ml centrifuge tube, into centrifuge tube be added 10% full Cilostazol to each experimental port be 100 μ l liquid.By liquid after being sufficiently mixed
Body is transferred in 96 orifice plates, and the liquid in each hole is 100 μ l.96 orifice plates are put into overnight incubation in deposited case.
(2) after overnight incubation cell is adherent according to experiment arrange and packet transaction cell after continue to be put into deposited case and be incubated for.
(3) plus MTT is detected: blotting cell conditioned medium, 10 μ l of 0.5%MTT is added in each hole under the conditions of being protected from light, and is protected from light and puts back to
It applies in case after continuing culture 4 hours and blots MTT, 150 μ l dimethyl sulfoxides are added, concussion is until bluish violet knot crystalline substance formazan is sufficiently molten
Solution.The light absorption value of each experimental port is measured at microplate reader OD 490nm.
2. colony formation
(1) it plants plate: by the cell dissociation tested, centrifugation, obtaining precipitating, be added suitable 10% into precipitating
Quan Pei carries out cell count, needs 10 according to each hole3-104Cell suspension volume required for cell calculates simultaneously is added to 6 holes
In plate, finally liquid trim in each hole to 2ml is placed in deposited case and is incubated for 7-10 days, centre is changed liquid 1 time with 10% full training.
(2) fixed: the supernatant that will form six orifice plates of colony abandons, and is washed 2 times with PBS, blots PBS, toward each
4% paraformaldehyde of 800 μ l is added in hole, fixes 30 minutes.
(3) it dyes: after the completion of fixed, being washed 2 times with PBS, 800 μ l0.1% crystal violet solutions are added into each hole, contaminate
Color 30 minutes
(4) it takes pictures: gently washing away extra crystal violet solution after the completion of dyeing under tap water, dry, taken pictures with camera.
3.EDU tests (cell proliferation experiment)
(1) it plants plate: the cell dissociation needed in experiment, centrifugation being precipitated, cell is resuspended, carries out cell count.It presses
According to addition 4 × 10 in each hole396 orifice plate of cell kind, and the liquid in each hole uniformly uses 10% to train the body for being fitted on 100 μ l entirely
Product.It is put into overnight incubation in deposited case and waits for that cell is adherent.
(2) it needs to handle cell according to experiment after cell is adherent.Continue culture experiment 24 hours.
(3) EDU indicates: blotting the full training in 96 orifice plates with liquid-transfering gun, the EDU of 50 μM of concentration is prepared using complete medium
The prepared full training containing EDU of 100 μ l is added into each hole for culture medium, is put into deposited case after continuing culture 2 hours and discards
Clearly, PBS is added, is washed 2 times on shaking table, each time is 5 minutes.
(3) fixed: to wash 96 orifice plates finished and blot PBS, 50 μ l, 4% paraformaldehyde is added into each hole and is consolidated
It is 30 minutes fixed.Paraformaldehyde is blotted after the completion of fixed, the glycine solution of 50 μ l 2mg/ml is added into each hole, by 96 holes
Plate is placed in decolorization swinging table, is continued to be incubated for and is abandoned glycine solution after five minutes, and PBS is added and washs on decolorization swinging table 1 time.Each
The triton solution of 100 μ l 0.5% is added in hole, 96 orifice plates are placed in decolorization swinging table and abandon triton solution after ten minutes, is added
PBS is washed 1 time on decolorization swinging table.
(4) dye: 100 μ l Apollo reaction solutions are added into each hole and carry out to the cell in 96 orifice plates by exhaustion PBS
Dyeing, is then incubated for 30 minutes on decolorization swinging table under conditions of being protected from light.
(5) supernatant is abandoned after the completion of dyeing, and the triton solution of 100 μ l 0.5% is added into each hole, is protected from light and shakes in decoloration
It is washed on bed 3 times, every time 10 minutes.100 μ l methanol are added into each hole to continue to rinse 2 times, are finally washed 1 time with PBS.With
Upper washing carries out on decolorization swinging table, and the time is 5 minutes.
(6) Hoechst33342 working solution is added into each hole, volume is 100 μ l, in the condition for being protected from light and be room temperature
Lower stationary incubation 30 minutes, PBS is washed after the completion of incubation.
(7) 96 orifice plates are placed under fluorescence inverted microscope and are observed, and taken pictures and save photo data, used
ImageJ carries out cell count.
4. Flow Cytometry detects apoptosis
(1) cell conditioned medium for needing to detect is completed in processing to collect, digests adherent cell with the pancreatin not comprising EDTA,
Pay attention to observing cellular morphology under the microscope, works as when the gap between cell rounding and cell and cell increases and use immediately
The supernatant collected before carries out termination digestion, collects cell suspension.It is then centrifuged for, obtains cell precipitation.With 4 degrees Celsius of PBS
Washing cell 1 time.Cell precipitation after being washed.
(2) Bing Buffer solution for later use is prepared according to the specification deionized water of the kit of detection apoptosis.
(3) the Bing Buffer solution that 1ml has diluted is added into cell precipitation, centrifugation is precipitated, again toward thin
100 μ l of Bing Buffer solution is added in born of the same parents' precipitating, it is anti-that 5 μ l of AnnexinV-FITC dye liquor then is added in the condition being protected from light
It answers 10 minutes, is eventually adding 5 μ l of PI dye liquor and reacts 10 minutes.Being eventually adding 390 microlitres of PBS solutions and mixing to system is 500 μ l.
It is protected from light cryo-conservation.
Upper machine testing apoptosis rate in (4) 1 hours.
Three, ATXN2L high expression is an important factor for influencing gastric cancer prognosis
Inventor is analyzed by cancer to the gastric cancer in TCGA database and cancer beside organism, finds the mRNA of ATXN2
Level is highly expressed (a of Fig. 1 schemes) in cancerous tissue.Then, it collects fresh stomach organization sample and carries out expressing quantity
Analysis finds that the expressing quantity of the ATXN2L of stomach organization is higher than cancer beside organism (b of Fig. 1 schemes).Further, south is had collected
The tissue specimen and clinical data of 167 Patients with Gastric Cancer of hospital are analyzed, wherein 48 are to receive to appease to control for the IV phase by stages
The patient for the treatment of, 119 are for the I-III phase and to receive the Patients with Gastric Cancer of Radical Gastrectomy by stages.Inventor has possessed this
167 patients of whole Follow-up Data carry out immunohistochemical analysis (c of Fig. 1 schemes) discovery, and the highly expressed patient of ATXN2L is later
Staging of Gastric Cancer patient in proportion it is higher, in I-III phase Patients with Gastric Cancer, trouble of the highly expressed patient of ATXN2L in recurrence
Proportion is higher compared to not recurring in person, in IV phase Patients with Gastric Cancer, patient of the highly expressed patient of ATXN2L in survival
Middle proportion is compared to dead low (d of Fig. 1 schemes).This prompt ATXN2L and gastric cancer by stages, existence, recurrence exist it is close
Relationship.Further, follow-up discovery, in the patient of IV phase palliative treatment, ATXN2L are carried out to 48 IV phase patients with gastric cancer
Highly expressed IV phase patients overall survival is considerably shorter than ATXN2L low expression person the time (e of Fig. 1 schemes).It is eradicated in the I-III phase
Follow-up discovery, ATXN2L highly expressed patients with gastric cancer recurrence-free survival phase (figure short compared with ATXN2L low expression are carried out in the patient of art
1 f figure).Layering survival analysis discovery is carried out to I-III phase Patients with Gastric Cancer, when the middle position recurrence-free survival of III phase Patients with Gastric Cancer
Between (g of Fig. 1 schemes) is obviously shortened compared with I, II phase.According to disease it is specific by stages, further, for the I-II phase (h of Fig. 1
Figure) and III phase (i of Fig. 1 schemes) patient's progress subgroup analysis, equally it can be found that the highly expressed patients with gastric cancer of ATXN2L is easier
Recurrence.
It is worth noting that being all made of oxaliplatin+fluorouracil in the patient of radical-ability postoperative adjuvant therapy and controlling
Treatment scheme.Cell experiment, which has proven to interference ATXN2L expression, influences less the cytotoxicity of fluorouracil, and to Ao Shali
Platinum has an impact.It is therefore contemplated that the highly expressed prognosis of ATXN2L that shows of clinical data is due to having occurred than low expression difference
Caused by Oxaliplatin-resistant.
Four, ATXN2L resists Apoptosis caused by oxaliplatin
It has been reported that the oxaliplatin stimulation of low concentration can cause liver cancer and colon carcinogenesis Epithelial and stromal to turn
Change, and experiment of the invention is, it was also found that low concentration (10 μ g/ml) oxaliplatin handles microscopically observation cellular morphology after cell
It was found that oxaliplatin can significantly be such that cellular morphology changes to spindle shape direction, and oxaliplatin is added after silencing ATXN2L
Then this morphologic change is unobvious (a of Fig. 2 schemes).EMT marker is dyed and is found, low concentration oxaliplatin inhibits E-
Cadherin and the expression for promoting vimentin albumen, and silencing ATXN2L can reverse this process.Show silencing ATXN2L energy
Reverse EMT caused by oxaliplatin.(b of Fig. 2 schemes).
There is document report cell that EMT occurs related to sensibility of the cell to drug.Therefore, the present invention considers
ATXN2L may take part in stomach cancer cell and resist Apoptosis caused by chemotherapeutics.Inventor is in shN, shATXN2L cell
The 5 FU 5 fluorouracil of the middle oxaliplatin that 30 μ g/ml are added and 50 μ g/ml continue Annexin V-FITC/ after culture 24 hours
The bis- transfection reagent box staining for flow of PI detect apoptosis rate, as a result, it has been found that apoptosis rate is aobvious after oxaliplatin group silencing ATXN2L
It writes and is higher than control group, and apoptosis rate and control group difference less (c of Fig. 2 schemes) after 5 FU 5 fluorouracil group silencing ATXN2L.
It thereby confirms ATXN2L and takes part in Apoptosis caused by stomach cancer cell resistance oxaliplatin.
It is completed with the oxaliplatin processing shATXN2L building of 0,10,15,20,30,40,50 μ g/ml concentration gradients steady
Turn cell strain, MTT is added after processing 24 hours and carries out MTT detection (d of Fig. 2 schemes), after as a result prompting silencing ATXN2L, gastric cancer is thin
Born of the same parents' strain increases the sensibility of oxaliplatin compared with control group.
Similarly, the stable cell strain passage kind plate that shATXN2L building is completed is done into colony formation, each hole kind 1
×104Cell is added 2 μ g/ml oxaliplatin of low concentration after cell is adherent in 24 hours and acts on 7 days, and primary training was replaced in centre
Base and drug, 7 days poststaining observation Colony forming situations (e of Fig. 2 schemes), as a result, it has been found that oxaliplatin group silencing is added
Cell colony forms number and is substantially less than control group after ATXN2L.
It is lost after oxaliplatin processing 6 hours of 50 μ g/ml are added in shN, shATXN2L#1, shATXN2L#2 cell
Supernatant is abandoned, is changed to and the anteserum-less substrate culture of the fluorescence probe DCFH-DA flow cytometer detection f of Fig. 2 (scheme) after twenty minutes, knot is added
The amount of the active oxygen generated in stomach cancer cell after fruit display silencing ATXN2L is higher than control group.
To sum up, the experimental results showed that ATXN2L, which participates in stomach cancer cell, resists Apoptosis caused by oxaliplatin.
Five, oxaliplatin causes the formation of stress granules by ATXN2L
The purpose of this experiment is to inquire into ATXN2L to influence the mechanism of oxaliplatin pharmaceutical sensibility.
Inventor carries out immunofluorescence experiment after stimulating stomach cancer cell using the oxaliplatin of gradient concentration, gradient timetable,
Ras GTP enzyme activation protein-binding protein 1 (G3BP1 albumen) is a molecular marker of stress granules, and general G3BP1 is in cell
Graininess is formed in matter can think to form stress granules in cell.As a result, it has been found that: ATXN2L and G3BP1 are thin in the cell
The expression of common location in cytoplasm, ATXN2L and G3BP1 under the stimulation of oxaliplatin in cell obviously increases, and with when
Between and concentration increase have and be incremented by the effect a of Fig. 3 (scheme).G3BP1 under conditions of cell is stimulated without oxaliplatin, in cell
And the less aggregation of ATXN2L forms graininess, after oxaliplatin is added, G3BP and ATXN2L are respectively formed graininess, that is, thinking stress
Particle is formed, and as the increase stress granules of time and concentration increase (a of Fig. 3 schemes).Equally, dense with 0,4,8,12 μ g/ml
The table that the RNA row qPCR detection in cell finds ATXN2L is extracted after spending oxaliplatin processing stomach cancer cell 24 hours of gradient
It is increased up to the concentration with oxaliplatin and increases (b of Fig. 3 schemes).
Have been verified that ATXN2L is related to oxaliplatin activity above, next, with Austria of 10 μ g/ml concentration
It is husky with Austria that husky benefit platinum extracts in cell RNA row qPCR after handling stomach cancer cell 0,12,24,48 hour detects ATXN2L expression
The relationship of sharp platinum action time.As a result prompt: the expression of ATXN2L increases the (c of Fig. 3 with the extended durations of action of oxaliplatin
Figure).Oxaliplatin stimulates the expression that can raise intracellular ATXN2L, and increases the formation of stress granules.
Does the formation of so stress granules influence the drug susceptibility of oxaliplatin? further immunofluorescence experiment
The results show that stress granules intracellular after non-disclosre ATXN2L have no change, Ao Shali after silencing ATXN2L compared with control group
The control group that oxaliplatin stimulation is added more merely in the stress granules that platinum stimulation generates significantly reduces (d of Fig. 3 schemes).
Result above prompt ATXN2L can lead to the primary of oxaliplatin by influencing the formation of intracellular stress granules
Property drug resistance, it is, the high expression of ATXN2L can be by promoting the formation of intracellular stress granules lead to oxaliplatin
Primary drug resistance, therefore, ATXN2L can be used as prediction gastric cancer oxaliplatin primary drug resistance marker.
Six, for predicting the kit of gastric cancer oxaliplatin primary drug resistance
Based on the studies above as a result, existing preparation public good in conjunction with this field about detection kit, can prepare and be used for
Predict the kit of gastric cancer oxaliplatin primary drug resistance.
Specifically, which is to predict gastric cancer according to the variation tendency of the content of ATXN2L in sample or content
The risk of oxaliplatin primary drug resistance, therefore it is prepared as expressing quantity detection kit.
Previous experiments are using immunohistochemistry or immuno-fluorescence assay expressing quantity, and discovery ATXN2L can predict stomach
Cancer oxaliplatin primary drug resistance, it is therefore preferable that expressing quantity detection kit is immunohistochemistry or Immunofluorescence test examination
Agent box.
Claims (5)
1. application of incoordination -2 sample albumen (ATXN2L) of element as the marker of prediction gastric cancer oxaliplatin primary drug resistance.
2. incoordination -2 sample albumen (ATXN2L) of element are preparing the kit for predicting gastric cancer oxaliplatin primary drug resistance
In purposes.
3. purposes according to claim 2, it is characterised in that: the kit be according to the content of ATXN2L in sample or
The variation tendency of content predicts the risk of gastric cancer oxaliplatin primary drug resistance.
4. purposes according to claim 2, it is characterised in that: the kit is expressing quantity detection kit.
5. purposes according to claim 4, it is characterised in that: the kit is immunohistochemistry or Immunofluorescence test
Kit.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910022553.XA CN109507436B (en) | 2019-01-10 | 2019-01-10 | Application of ATXN2L as marker for predicting oxaliplatin primary drug resistance of gastric cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910022553.XA CN109507436B (en) | 2019-01-10 | 2019-01-10 | Application of ATXN2L as marker for predicting oxaliplatin primary drug resistance of gastric cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109507436A true CN109507436A (en) | 2019-03-22 |
| CN109507436B CN109507436B (en) | 2021-09-03 |
Family
ID=65757542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910022553.XA Active CN109507436B (en) | 2019-01-10 | 2019-01-10 | Application of ATXN2L as marker for predicting oxaliplatin primary drug resistance of gastric cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109507436B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036527A1 (en) * | 1998-01-19 | 1999-07-22 | Hunan Medical University | An ataxin-2 like gene |
| EP1514116A1 (en) * | 2002-06-17 | 2005-03-16 | Centre National De La Recherche Scientifique (Cnrs) | Oxaliplatin anti-resistance agent |
| US20080280768A1 (en) * | 2007-01-30 | 2008-11-13 | Oncotech, Inc. | Reagents and Methods for Predicting Drug Resistance |
| CN103055326A (en) * | 2012-12-20 | 2013-04-24 | 广州医学院附属肿瘤医院 | Application of TCRP1 gene in the preparation of tumor cell platinum resistance reversal agent |
-
2019
- 2019-01-10 CN CN201910022553.XA patent/CN109507436B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036527A1 (en) * | 1998-01-19 | 1999-07-22 | Hunan Medical University | An ataxin-2 like gene |
| EP1514116A1 (en) * | 2002-06-17 | 2005-03-16 | Centre National De La Recherche Scientifique (Cnrs) | Oxaliplatin anti-resistance agent |
| US20080280768A1 (en) * | 2007-01-30 | 2008-11-13 | Oncotech, Inc. | Reagents and Methods for Predicting Drug Resistance |
| CN103055326A (en) * | 2012-12-20 | 2013-04-24 | 广州医学院附属肿瘤医院 | Application of TCRP1 gene in the preparation of tumor cell platinum resistance reversal agent |
Non-Patent Citations (5)
| Title |
|---|
| DAVID NONIS ET AL.,: "Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking", 《CELLULAR SIGNALLING》 * |
| IOANNIS PANAGOPOULOS ET AL.: "Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma", 《ONCOTARGET》 * |
| MICHÈLE SABBAH ET AL.,: "Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers", 《DRUG RESIST UPDAT.》 * |
| YUAN QIN ET AL.,: "Dihydroartemisinin inhibits EMT induced by platinum-based drugs via Akt-Snail pathway", 《ONCOTARGET》 * |
| 陈晓晨: "脊髓小脑共济性失调2型的修饰基因变异及自然选择对ATXN2基因的影响", 《中国博士学位论文全文数据库》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109507436B (en) | 2021-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | 5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells | |
| Pacheco-Velázquez et al. | Energy metabolism drugs block triple negative breast metastatic cancer cell phenotype | |
| Wang et al. | Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway | |
| Rehman et al. | FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer | |
| Liu et al. | microRNA-218 suppresses the proliferation, invasion and promotes apoptosis of pancreatic cancer cells by targeting HMGB1 | |
| Chen et al. | Estrogen receptor mediates the radiosensitivity of triple-negative breast cancer cells | |
| Li et al. | NOP14 inhibits melanoma proliferation and metastasis by regulating Wnt/β-catenin signaling pathway | |
| Dian et al. | MST4 negatively regulates the EMT, invasion and metastasis of HCC cells by inactivating PI3K/AKT/Snail1 axis | |
| Dongqing et al. | The effect and mechanism of vascular endothelial growth factor (VEGF) on tumor angiogenesis in gallbladder carcinoma | |
| Jang et al. | Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes | |
| Zhang et al. | TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway. | |
| Chen et al. | Overexpression of HACE 1 in gastric cancer inhibits tumor aggressiveness by impeding cell proliferation and migration | |
| Zhao et al. | Long non-coding RNA-ENST00000434223 suppresses tumor progression in gastric cancer cells through the Wnt/β-catenin signaling pathway | |
| Zhang et al. | The role of nucleolar spindle‐associated protein 1 in human ovarian cancer | |
| Liu et al. | Characteristics and clinical significance of polyploid giant cancer cells in laryngeal carcinoma | |
| Luan et al. | MiR-769-5p functions as an oncogene by down-regulating RYBP expression in gastric cancer. | |
| Li et al. | Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma | |
| Li et al. | Down-regulation of PRR11 affects the proliferation, migration and invasion of osteosarcoma by inhibiting the Wnt/β-catenin pathway | |
| Pardella et al. | Therapy-induced stromal senescence promoting aggressiveness of prostate and ovarian cancer | |
| Qu et al. | LncRNA AOC4P affects biological behavior of gastric cancer cells through MAPK signaling pathway. | |
| Ge et al. | Role of long non-coding RNA SNHG1 in occurrence and progression of ovarian carcinoma. | |
| Wang et al. | Upregulation of ALDH1B1 promotes tumor progression in osteosarcoma | |
| Fan et al. | Octreotide-paclitaxel conjugate reverses paclitaxel resistance by p38 mitogen-activated protein kinase (MAPK) signaling pathway in A2780/taxol human ovarian cancer cells | |
| CN109529018A (en) | ATXN2L is used to prepare the purposes of the drug of reversing stomach Oxaliplatin-resistant | |
| Kong et al. | Effects of miRNA‐140 on the Growth and Clinical Prognosis of SMMC‐7721 Hepatocellular Carcinoma Cell Line |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |